Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00394173 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00394173 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 180 participants.
The verdict
NCT00394173, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
Interventions
- DRUG Placebo
- DRUG DNK333
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00394173
The ClinicalTrials.gov registry entry for NCT00394173 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00394173 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00394173 about?
NCT00394173 is a clinical study titled "Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)". The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.
What is the current status of trial NCT00394173?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2006-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00394173?
The interventions under investigation include: Placebo (DRUG), DNK333 (DRUG).
Who is sponsoring clinical trial NCT00394173?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.